Teva Metformin NDMA Settlement $5.55 Million for Diabetes Drug Buyers
The Teva Metformin NDMA Settlement $5.55 Million for Diabetes Drug Buyers settlement offers $5.55M in total to eligible claimants who be a member of the settlement class as defined in the long form notice/settlement agreement. The filing deadline has not yet been announced. Proof of purchase is not required.
Deadline: No deadline specified
Total amount allocated for all claims
Estimated amount per eligible claim
No proof of purchase needed — anyone eligible can file a claim
Submit a completed claim form via InReMetforminSettlement.com by the deadline. Provide information sufficient to show you are a qualifying class member and that you purchased covered metformin products during the settlement’s covered timeframe. Documentation may include purchase records (e.g., receipts/invoices), prescription information, or other proof of purchase/ownership as specified in the Long Form Notice and claim instructions.
Settlement Summary
Metformin is one of the most widely used medications for type 2 diabetes, prescribed for millions of people worldwide. In recent years, regulators and researchers identified trace contamination of NDMA (N-nitrosodimethylamine), a chemical that is considered a probable human carcinogen, in certain metformin products. The issue led to FDA communications, investigations, and product actions, while class members alleged that consumers and patients—through misleading marketing and sales practices—were not adequately warned about the contamination risk and the impact on drug quality and safety. The lawsuit—In re Metformin Marketing and Sales Practices Litigation, filed in the U.S. District Court for the District of New Jersey—culminated in a $5.55 million settlement fund intended for eligible diabetes drug buyers. A class action like this is significant because it pools claims from many consumers, making it practical to seek compensation for alleged harm tied to NDMA contamination, procurement, and purchasing decisions. The case also underscores how pharmaceutical supply-chain and manufacturing controls can affect patient safety, and it reflects ongoing scrutiny by regulators; in particular, it connects to industry-facing expectations around contamination prevention, quality systems, and transparency under FDA oversight and related guidance, especially as public health agencies flagged NDMA concerns and risk classification. Broader implications include heightened vigilance across the generics and branded-drug ecosystem, since multiple manufacturers can be affected by similar sourcing or production processes. Similar NDMA-related disputes have emerged in other drug contexts as agencies evaluate contamination risks and as plaintiffs argue that companies should have disclosed relevant safety information sooner or more clearly. For patients and healthcare buyers, the settlement is a reminder that drug safety is not only about active ingredients, but also about how those ingredients are produced, tested, and communicated—an area where compliance expectations continue to evolve as NDMA findings and enforcement attention grow, and where future litigation may focus on similar marketing and warning conduct in the metformin marketplace
Entities Involved
Related Topics
Eligibility Requirements
- Be a member of the settlement class as defined in the Long Form Notice/Settlement Agreement
- Have purchased covered metformin products that were marketed/sold during the class period alleged in the lawsuit
- Provide the information requested on the claim form (and any required documentation) to show entitlement
- Submit a claim by the deadline stated in the official settlement notice
Featured Investigations
Important Notice About Filing Claims
Submitting false information in a settlement claim is considered perjury and will result in your claim being rejected. Fraudulent claims harm legitimate class members and may result in legal consequences.
If you are unsure about your eligibility for this settlement, please visit the official settlement administrator’s website using the link provided above. Review the eligibility criteria carefully before submitting a claim.
Class Action Champion is an independent information resource and is not affiliated with any settlement administrator, law firm, or court. We provide settlement information as a service to help connect eligible class members with legitimate settlements.